Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: A report from the late effects surveillance system

Pediatric Blood and Cancer

Volumn 48, Issue 4, 2007, Pages 447-452

  Stohr W ^a   Paulides, M ^a   Bielack, S ^b   Jurgens H ^c   Treuner, J ^d   Rossi, R ^e   Langer, T ^a   Beck, J D ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b OLGAHOSPITAL   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d Hematology   (Germany)

^e VIVANTES KLINIKUM NEUKÖLLN   (Germany)

Author keywords

Cancer; Children; Fanconi syndrome; Ifosfamide; Nephrotoxicity; Tubulopathy

Indexed keywords

CARBOPLATIN; CISPLATIN; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; VINCRISTINE;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD CANCER; EWING SARCOMA; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSURIA; HUMAN; HYPOCAPNIA; HYPOPHOSPHATEMIA; INCIDENCE; INFANT; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEPHROTOXICITY; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR; SARCOMA; SIDE EFFECT; SOFT TISSUE SARCOMA;

ABDOMEN; ADOLESCENT; AGE FACTORS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOPHOSPHATEMIA; IFOSFAMIDE; INCIDENCE; INFANT; KIDNEY DISEASES; KIDNEY TUBULES; MALE; PRODUCT SURVEILLANCE, POSTMARKETING; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTEINURIA; RADIOTHERAPY; RISK FACTORS; SARCOMA;

EID: 33847361458     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20858     Document Type: Article

References (44)

1. Skinner R, Sharkey IM, Pearson AD, et al. Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 1993;11:173-190.
2. Rossi R, Kleta R, Ehrich JH. Renal involvement in children with malignancies. Pediatr Nephrol 1999;13:153-162.
3. Skinner R. Chronic ifosfamide nephrotoxicity in children, Med Pediatr Oncol 2003;41:190-197.
4. Heney D, Lewis IJ, Bailey CC. Acute ifosfamide-induced tubular toxicity [letter; comment]. Lancet 1989;2:103-104.
5. Moncrieff M, Foot A. Fanconi syndrome after ifosfamide. Cancer Chemother Pharmacol 1989;23:121-122.
6. Skinner R, Pearson AD, Price L, et al. Nephrotoxicity of ifosfamide in children [letter; comment]. Lancet 1989;2:159.
7. Burk CD, Restaino I, Kaplan BS, et al. Ifosfamide-induced renal tubular dysfunction and rickets in children with Wilms tumor [see comments]. J Pediatr 1990;117:331-335.
8. De Schepper J, Stevens G, Verboven M, et al. Ifosfamide-induced Fanconi's syndrome with growth failure in a 2-year-old child. Am J Pediatr Hematol Oncol 1991;13:39-41.
9. Suarez A, McDowell H, Niaudet P, et al. Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: An International Society of Pediatric Oncology report. J Clin Oncol 1991;9:2177-2182.
10. Van Gool S, Brock P, Wijndaele G, et al. Reversible hypophosphatemic rickets following ifosfamide treatment [see comments]. Med Pediatr Oncol 1992;20:254-257.
11. Morland BJ, Mann JR, Milford DV, et al. Ifosfamide nephrotoxicity in children: Histopathological features in two cases [published erratum appears in Med Pediatr Oncol 1997 Jan;28(1):80]. Med Pediatr Oncol 1996;27:57-61.
12. Ashraf MS, Skinner R, English MW, et al. Late reversibility of chronic ifosfamide-associated nephrotoxicity in a child. Med Pediatr Oncol 1997;28:62-64.
13. Loebstein R, Atanackovic G, Bishai R, et al. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharmacol 1999;39:454~461.
14. Skinner R, Pearson AD, English MW, et al. Risk factors for ifosfamide nephrotoxicity in children [see comments]. Lancet 1996;348:578-580.
15. Rossi R, Godde A, Kleinebrand A, et al. Concentrating capacity in ifosfamide-induced severe renal dysfunction. Ren Fail 1995;17:551-557.
16. Smeitink J, Verreussel M, Schroder C, et al. Nephrotoxicity associated with ifosfamide. Eur J Pediatr 1988;148:164-166.
17. Prasad VK, Lewis IJ, Aparicio SR, et al. Progressive glomerular toxicity of ifosfamide in children. Med Pediatr Oncol 1996;27:149-155.
18. Rossi R, Danzebrink S, Hillebrand D, et al. Ifosfamide-induced subclinical nephrotoxicity and its potentiation by cisplatinum. Med Pediatr Oncol 1994;22:27-32.
19. Pratt CB, Meyer WH, Jenkins JJ, et al. Ifosfamide, Fanconi's syndrome, and rickets. J Clin Oncol 1991;9:1495-1499.
20. Rossi R, Pleyer J, Schafers P, et al. Development of ifosfamide-induced nephrotoxicity: Prospective follow-up in 75 patients. Med Pediatr Oncol 1999;32:177-182.
21. Lee BS, Lee JH, Kang HG, et al. Ifosfamide nephrotoxicity in pediatric cancer patients. Pediatr Nephrol 2001;16:796-799.
22. Skinner R, Cotterill SJ, Stevens MC. Risk factors for nephrotoxicity after ifosfamide treatment in children: A UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group. Br J Cancer 2000;82:1636-1645.
23. Stevens MC, Brandis M. Incidence and etiology of ifosfamide nephrotoxicity: Report of a meeting held in Rhodes, Greece, October 3, 1991, sponsored by Asta Medica, Frankfurt, Germany. Med Pediatr Oncol 1993;21:640-644.
24. Caron HN, Abeling N, van Gennip A, et al. Hyperaminoaciduria identifies patients at risk of developing renal tubular toxicity associated with ifosfamide and platinate containing regimens. Med Pediatr Oncol 1992;20:42-47.
25. Rossi R, Godde A, Kleinebrand A, et al. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: Analysis of 120 patients. J Clin Oncol 1994;12:159-165.
26. Ashraf MS, Brady J, Breatnach F, et al. Ifosfamide nephrotoxicity in paediatric cancer patients. Eur J Pediatr 1994;153:90-94.
27. Rossi R, Schäfers P, Pleyer J, et al. The influence of short versus continuous ifosfamide infusion on the development of renal tubular impairment. Int J Pediatr Hematol Oncol 1997;4:393-399.
28. Raney B, Ensign LG, Foreman J, et al. Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. Am J Pediatr Hematol Oncol 1994;16:286-295.
29. McCune JS, Friedman DL, Schuetze S, et al. Influence of age upon Ifosfamide-induced nephrotoxicity. Pediatr Blood Cancer 2004;42:427-432.
30. Shaw PJ, Eden T. Ifosfamide in paediatric oncology: Tried but not tested? Lancet 1990;335:1022-1023.
31. Kamen BA, Frenkel E, Colvin OM. Ifosfamide: Should the honeymoon be over? J Clin Oncol 1995;13:307-309.
32. Womer RB. Ifosfamide and paediatrics: Should this marriage be saved? Eur J Cancer 1996;32A:1100-1101.
33. Aleksa K, Woodland C, Koren G. Young age and the risk for ifosfamide-induced nephrotoxicity: A critical review of two opposing studies. Pediatr Nephrol 2001;16:1153-1158.
34. Langer T, Henze G, Beck J. Basic methods and the developing structures of a late effects surveillance system (LESS) in the long-term follow-up of pediatric cancer patients in Germany. Med Pediatr Oncol 2000;34:348-351.
35. Langer T, Stohr W, Bielack S, et al. Late effects surveillance system for sarcoma patients. Pediatr Blood Cancer 2004;42:373-379.
36. Langer T, Stohr W, Paulides M, et al. Prospective multicenter registration of major late sequelae in sarcoma patients using the late effects surveillance system (LESS). Klin Padiatr 2005;217:176-181.
37. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999;28:964-974.
38. DCTD, NCI, NIH and DHHS Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events Version 3.0. http://ctep.cancer.gov 2003.
39. MacLean FR, Skinner R, Hall AG, et al. Acute changes in urine protein excretion may predict chronic ifosfamide nephrotoxicity: A preliminary observation. Cancer Chemother Pharmacol 1998;41:413-416.
40. Brodehl J, Gellissen K, Weber HP. Postnatal development of tubular phosphate reabsorption. Clin Nephrol 1982;17:163-171.
41. Rossi R, Danzebrink S, Linnenburger K, et al. Assessment of tubular reabsorption of sodium, glucose, phosphate and amino acids based on spot urine samples. Acta Paediatr 1994;83:1282-1286.
42. Marina NM, Poquette CA, Cain AM, et al. Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas. J Pediatr Hematol Oncol 2000;22:112-118.
43. Elias AD, Ayash LJ, Eder JP, et al. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J Clin Oncol 1991;9:320-327.
44. Goren MP, Wright RK, Pratt CB, et al. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy. Cancer Res 1987;47:1457-1460.